
|Videos|January 17, 2014
The Utility of the Myriad myRisk Hereditary Cancer Test
Author(s)Elizabeth Garner, MD, MPH
Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.
Advertisement
Clinical Pearls
Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary CancerTMTest.
- MyRisk is a genetic test that looks for mutations in 25 genes that are known to be associated with significantly elevated risk for cancer
- There are eight major cancers the test can detect, including breast cancer, ovarian cancer, melanoma, and endometrial cancer.
- The test allows physicians to increase the rate of detection for individuals that have mutations or who have hereditary cancer syndromes
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































